News

Nursing ethics expert Katherine Brown-Saltzman, MA, RN, shares insights on how to manage difficult ethical issues when treating patients with cancer.

Expert advice for administering and monitoring liso-cel in patients with follicular lymphoma.

The microbiota-based therapy MaaT013 showed promising efficacy and manageable safety in those with acute GVHD with gastrointestinal involvement.

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025.

Patient K.C. transitions from high-risk care to invasive mammary carcinoma treatment under the care and support of a breast cancer advanced practice provider.

Age and having children were found to affect whether premenopausal women with breast cancer opted for fertility preservation.

Risvutatug rezetecan, an antibody-drug conjugate was granted FDA orphan drug designation for use in patients with small cell lung cancer.

Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, discusses end-of-life care from a multidisciplinary perspective.

Oncology nurses and APPs are key players in patient education on precision medicine.

Breast cancer survivors improved cognitive outcomes with both real and sham acupuncture, but real acupuncture showed greater gains.

As CAR T-cell therapy expands to solid tumors, oncology nurses play a key role in monitoring, educating, and supporting patients.

Giredestrant displayed a safety profile consistent with prior findings and had a lower rate of discontinuation compared with standard endocrine therapy.

Frontline maintenance tucatinib plus trastuzumab and pertuzumab increased progression-free survival in patient with HER2-positive metastatic breast cancer.

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj across all amivantamab indications.

The FDA has greenlit treatment with rucaparib for previously treated patients with BRCA-mutated metastatic castration-resistant prostate cancer.

A mobile health intervention was linked with an increase in general and cancer-specific QOL in adolescent and young adult breast cancer survivors.

Hormone replacement therapy was associated with a lower risk of developing BRCA1– or BRCA2–mutated breast cancer among those already at higher risk.

The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer.

Subcutaneous daratumumab plus teclistamab improved survival outcomes in patients with R/R multiple myeloma vs standard daratumumab-based regimens.

Preoperative radiation and pembrolizumab improved T-cell infiltration in patients with higher-risk, HR-positive, HER2-negative, early-stage breast cancer.

Phase 2 data demonstrated similar pharmacokinetic profiles between subcutaneous azacitidine and an oral combination of azacitidine and cedazuridine.

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of progression-free survival.

Patients with relapsed/refractory large B-cell lymphoma treated with glofitamab or epcoritamab experienced early disease progression.

Lillian Rodich, PA-C, MPH, discusses how integrative oncology can give patients practical strategies for managing symptoms, regardless of financial barriers.

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk large B-cell lymphoma.

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

Phase 3 trial results demonstrated a significant benefit with the BTK inhibitor pirtobrutinib vs bendamustine plus rituximab in patients with untreated CLL/SLL.